Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Teva Files Patent Infringement Lawsuit Against Lilly

By Meagan Parrish | October 26, 2017

Teva Pharmaceuticals Industries is hoping to block a migraine medication made by Eli Lilly from entering the market.

According to a report in Reuters, Israeli-based Teva filed a patent infringement lawsuit in federal court in Boston against the American pharmaceutical company. The suit alleges that Lilly’s migraine treatment, galcanezumab infringes on five of Teva’s patents.

Teva’s suit claims that Lilly knew about the patents covering Teva’s drug fremanezumab, but was nevertheless working to gain FDA approval for galcanezumab.

Teva is hope to win damages and an injunction that will stop Lilly from manufacturing or selling galcanezumab.

Several pharmaceutical companies have been racing to develop new drugs to treat migraines, which currently affect about 38 million Americans. The newest class of treatments target a neurotransmitter called the calcitonin gene-related peptide (CGPR).

According to estimates by Evercore ISI, the potential market for CPGR drugs is $8-$10 billion.

In addition to the medications like fremanezumab and galcanezumab, Amgen has also developed a CPGR drug called erenumab.  


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE